Generation of tumor specific immunity in canine osteosarcoma through dendritic cell hyperactivation

通过树突状细胞过度激活在犬骨肉瘤中产生肿瘤特异性免疫

基本信息

  • 批准号:
    10688274
  • 负责人:
  • 金额:
    $ 65.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Despite substantial improvements in therapeutic strategies, generating robust anti-tumor immune responses in human cancers with a lower somatic mutation burden remains a substantial challenge. Recent data indicate that a critical player in this process, dendritic cells (DCs), fail to effectively elicit efficient and durable T cell responses unless they have entered a unique state of hyperactivation. In this setting, DCs exhibit enhanced migration to local lymph nodes (LNs) and sustained secretion of IL-1β, a cytokine critical for memory T cell formation. In mouse tumor models, vaccination with whole tumor lysate plus an adjuvant consisting of the TLR 7/8 agonist R848 (resiquimod) in combination with a unique isolated lysophosphatidylcholine (22:0 Lyso PC) promotes DC hyperactivation, expansion of antigen specific CD8+ T cells, and robust rejection of tumors. While these findings are encouraging and suggest that identification of specific neoantigens is not necessary to prime and expand a pool of cytotoxic T cells (CTLs), validation and optimization of this approach necessitates the use of a model system that more closely recapitulates human cancers with respect to immune landscape. As such, the purpose of this proposal is to use spontaneous canine cancer, specifically osteosarcoma (OS), as a bridging animal model to validate the utility of DC hyperactivation as a foundational element for generation of robust anti-tumor immunity. The central hypothesis to be tested in this application is that combining hyperactivation of DCs with WTL derived neoantigen will expand a diverse and tumor-specific population of CTLs capable of eliminating residual microscopic metastatic OS tumor cells in dogs following primary tumor removal (amputation). We further predict, that combining DC hyperactivation/WTL with a novel tumor microenvironment (TME) conditioning regimen consisting of toceranib/losartan/ladarixin will enhance the objective response rate in dogs that develop macroscopic lung metastasis. To accomplish this, we will conduct a prospective randomized clinical trial in dogs with OS combining amputation and standard of care carboplatin chemotherapy with adjuvant alone or adjuvant+WTL. Dogs that develop lung metastasis will then be treated with the TME conditioning regimen in combination with adjuvant+WTL. A biobank of tissue samples and blood will be collected from dogs enrolled in these trials including matched primary/metastatic tumors and associated LNs, whole blood, plasma, PBMCs, cell-free DNA, and samples from the vaccine draining LNs. These will be used to perform a set of complementary assays designed to characterize the immune microenvironment and tumor genome over the course of relapse/resistance, credential a novel neoantigen prediction pipeline, and evaluate antigen specific T cell responses. An outstanding team with complementary sets of expertise across clinical trials, translational oncology, comparative genomics, and immuno-oncology has been assembled to ensure stated milestones are achieved. This is bolstered by a dynamic collaboration with our industry partner, Corner Therapeutics, which is committed to supporting this work to facilitate optimization and successful translation into human patients.
项目摘要 尽管在治疗策略上有了实质性的改进,但在小鼠中产生强大的抗肿瘤免疫应答仍然是一个挑战。 具有较低体细胞突变负荷的人类癌症仍然是一个重大挑战。最近的数据显示, 在这个过程中,树突状细胞(DCs)是一个关键的参与者,它不能有效地引发有效和持久的T细胞应答 除非他们进入了一种特殊的超激活状态在这种情况下,发展中国家表现出增强的迁移, 局部淋巴结(LN)和持续分泌IL-1β,一种对记忆T细胞形成至关重要的细胞因子。在 小鼠肿瘤模型,用全肿瘤裂解物加上由TLR 7/8激动剂组成的佐剂接种 R848(瑞喹莫特)与独特的分离的溶血磷脂酰胆碱(22:0 Lyso PC)组合促进DC 超活化、抗原特异性CD 8 + T细胞的扩增和肿瘤的强烈排斥。虽然这些发现 是令人鼓舞的,并表明识别特定的新抗原是不必要的,以引发和扩大 细胞毒性T细胞(CTL)池,验证和优化这种方法需要使用一个模型 系统,更接近地概括人类癌症的免疫景观。因此,目的 这项建议的一个重要方面是使用自发性犬癌,特别是骨肉瘤(OS),作为桥接 动物模型,以验证DC超活化作为产生 强大的抗肿瘤免疫力。在本申请中要测试的中心假设是, 用WTL衍生的新抗原超活化DC将扩增多样化的和肿瘤特异性的CTL群体 能够消除狗中原发性肿瘤切除后残留的显微镜下转移性OS肿瘤细胞 (截肢)。我们进一步预测,将DC超活化/WTL与新的肿瘤微环境相结合, (TME)由toceranib/losartan/ladarixin组成的预处理方案将提高客观缓解率 发生肉眼可见肺转移的狗。为了实现这一目标,我们将进行一项前瞻性随机 在OS犬中联合截肢和标准治疗卡铂化疗与辅助治疗的临床试验 单独或佐剂+WTL。发生肺转移的犬随后将接受TME预处理 方案与佐剂+WTL组合。将从犬中收集组织样本和血液的生物样本库 包括匹配的原发性/转移性肿瘤和相关LN,全血,血浆, PBMC、无细胞DNA和来自疫苗引流淋巴结的样品。这些将用于执行一组 设计用于表征免疫微环境和肿瘤基因组的互补测定, 复发/耐药过程,证明一种新的新抗原预测管道,并评估抗原特异性T细胞 细胞反应。一个优秀的团队,在临床试验、翻译和临床试验方面具有互补的专业知识。 肿瘤学,比较基因组学和免疫肿瘤学已经组装,以确保所述的里程碑是 办妥了一批这得益于我们与行业合作伙伴Corner Therapeutics的动态合作, 致力于支持这项工作,以促进优化和成功转化为人类患者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Cheryl A London其他文献

Tissue factor-targeted immunotherapy of melanoma and triple negative breast cancer using a second generation ICON
  • DOI:
    10.1186/2051-1426-3-s2-p304
  • 发表时间:
    2015-11-04
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Zhiwei Hu;Elizabeth McMichael;Amanda Campbell;Cheryl A London;William E Carson
  • 通讯作者:
    William E Carson

Cheryl A London的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Cheryl A London', 18)}}的其他基金

Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 65.78万
  • 项目类别:
Resources and workforce development for the New England Regional Biosafety Laboratory
新英格兰地区生物安全实验室的资源和劳动力发展
  • 批准号:
    10793931
  • 财政年份:
    2023
  • 资助金额:
    $ 65.78万
  • 项目类别:
Cross-Disciplinary Research Training for Veterinary Students
兽医学生跨学科研究培训
  • 批准号:
    10666627
  • 财政年份:
    2022
  • 资助金额:
    $ 65.78万
  • 项目类别:
Enhancing the efficacy of immunotherapy in DLBCL using rational combination approaches
使用合理的组合方法提高DLBCL免疫治疗的疗效
  • 批准号:
    10247897
  • 财政年份:
    2017
  • 资助金额:
    $ 65.78万
  • 项目类别:
Enhancing the efficacy of immunotherapy in DLBCL using rational combination approaches
使用合理的组合方法提高DLBCL免疫治疗的疗效
  • 批准号:
    10256800
  • 财政年份:
    2017
  • 资助金额:
    $ 65.78万
  • 项目类别:
COMPARTIVE ANIMAL CORE
比较动物核心
  • 批准号:
    8516645
  • 财政年份:
    2013
  • 资助金额:
    $ 65.78万
  • 项目类别:
c-Kit Mutations and Their Role in Tumor Biology
c-Kit 突变及其在肿瘤生物学中的作用
  • 批准号:
    6785866
  • 财政年份:
    2002
  • 资助金额:
    $ 65.78万
  • 项目类别:
c-Kit Mutations and Their Role in Tumor Biology
c-Kit 突变及其在肿瘤生物学中的作用
  • 批准号:
    7219356
  • 财政年份:
    2002
  • 资助金额:
    $ 65.78万
  • 项目类别:
c-Kit Mutations and Their Role in Tumor Biology
c-Kit 突变及其在肿瘤生物学中的作用
  • 批准号:
    6546067
  • 财政年份:
    2002
  • 资助金额:
    $ 65.78万
  • 项目类别:
c-Kit Mutations and Their Role in Tumor Biology
c-Kit 突变及其在肿瘤生物学中的作用
  • 批准号:
    6640368
  • 财政年份:
    2002
  • 资助金额:
    $ 65.78万
  • 项目类别:

相似海外基金

AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 65.78万
  • 项目类别:
Augmenting the Quality and Duration of the Immune Response with a Novel TLR2 Agonist-Aluminum Combination Adjuvant
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10499193
  • 财政年份:
    2021
  • 资助金额:
    $ 65.78万
  • 项目类别:
A Novel TLR5 Agonist-Based Adjuvant for Poliovirus Vaccine
一种基于 TLR5 激动剂的新型脊髓灰质炎病毒疫苗佐剂
  • 批准号:
    9305008
  • 财政年份:
    2016
  • 资助金额:
    $ 65.78万
  • 项目类别:
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
血管生成拮抗剂加CD40-TLR激动剂佐剂组合疫苗
  • 批准号:
    8054408
  • 财政年份:
    2010
  • 资助金额:
    $ 65.78万
  • 项目类别:
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
血管生成拮抗剂加CD40-TLR激动剂佐剂组合疫苗
  • 批准号:
    7909550
  • 财政年份:
    2010
  • 资助金额:
    $ 65.78万
  • 项目类别:
Malaria vaccines modified with TLR agonist adjuvant
TLR 激动剂佐剂修饰的疟疾疫苗
  • 批准号:
    8126073
  • 财政年份:
    2010
  • 资助金额:
    $ 65.78万
  • 项目类别:
Malaria vaccines modified with TLR agonist adjuvant
TLR 激动剂佐剂修饰的疟疾疫苗
  • 批准号:
    7899536
  • 财政年份:
    2009
  • 资助金额:
    $ 65.78万
  • 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
  • 批准号:
    7362543
  • 财政年份:
    2007
  • 资助金额:
    $ 65.78万
  • 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
  • 批准号:
    7502193
  • 财政年份:
    2007
  • 资助金额:
    $ 65.78万
  • 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
  • 批准号:
    7911043
  • 财政年份:
    2007
  • 资助金额:
    $ 65.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了